NEW YORK, Feb. 11 - Deltagen has dipped its toes deeper into drug-development waters with its proposed acquisition of Bristol-Myers Squibb's Pharma Research Labs division.
 
The acquisition, which will cost roughly $23.5 million in stock, gives Deltagen the keys to a small molecule-drug discovery firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.